ANVS
Annovis Bio, Inc.NYSEHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.46
P/S
0.00
EV/EBITDA
660.03
DCF Value
$950.27
FCF Yield
-1844.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-159.4%
ROA
-136.9%
ROIC
-170.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-9.8M | $-0.40 |
| FY 2025 | $0.00 | $-28.9M | $-1.40 |
| Q3 2025 | $0.00 | $-7.3M | $-0.37 |
| Q2 2025 | $0.00 | $-6.2M | $-0.32 |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$25.67
Target (Median)
$26.00
Target Range
$21.00 - $30.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NYSE
Beta
1.36
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.